An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants

Deborah A. Hall, Robin M. Voigt, Thaisa M. Cantu-Jungles, Bruce Hamaker, Phillip A. Engen, Maliha Shaikh, Shohreh Raeisi, Stefan J. Green, Ankur Naqib, Christopher B. Forsyth, Tingting Chen, Richard Manfready, Bichun Ouyang, Heather E. Rasmussen, Shahriar Sedghi, Christopher G. Goetz and Ali Keshavarzian ()
Additional contact information
Deborah A. Hall: Rush University Medical Center
Robin M. Voigt: Rush University Medical Center
Thaisa M. Cantu-Jungles: Rush University Medical Center
Bruce Hamaker: Rush University Medical Center
Phillip A. Engen: Rush University Medical Center
Maliha Shaikh: Rush University Medical Center
Shohreh Raeisi: Rush University Medical Center
Stefan J. Green: Rush University Medical Center
Ankur Naqib: Rush University Medical Center
Christopher B. Forsyth: Rush University Medical Center
Tingting Chen: Purdue University
Richard Manfready: Rush University Medical Center
Bichun Ouyang: Rush University Medical Center
Heather E. Rasmussen: Rush University Medical Center
Shahriar Sedghi: Mercer University
Christopher G. Goetz: Rush University Medical Center
Ali Keshavarzian: Rush University Medical Center

Nature Communications, 2023, vol. 14, issue 1, 1-14

Abstract: Abstract A pro-inflammatory intestinal microbiome is characteristic of Parkinson’s disease (PD). Prebiotic fibers change the microbiome and this study sought to understand the utility of prebiotic fibers for use in PD patients. The first experiments demonstrate that fermentation of PD patient stool with prebiotic fibers increased the production of beneficial metabolites (short chain fatty acids, SCFA) and changed the microbiota demonstrating the capacity of PD microbiota to respond favorably to prebiotics. Subsequently, an open-label, non-randomized study was conducted in newly diagnosed, non-medicated (n = 10) and treated PD participants (n = 10) wherein the impact of 10 days of prebiotic intervention was evaluated. Outcomes demonstrate that the prebiotic intervention was well tolerated (primary outcome) and safe (secondary outcome) in PD participants and was associated with beneficial biological changes in the microbiota, SCFA, inflammation, and neurofilament light chain. Exploratory analyses indicate effects on clinically relevant outcomes. This proof-of-concept study offers the scientific rationale for placebo-controlled trials using prebiotic fibers in PD patients. ClinicalTrials.gov Identifier: NCT04512599.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-023-36497-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-36497-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-36497-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().